<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335454">
  <stage>Registered</stage>
  <submitdate>7/05/2010</submitdate>
  <approvaldate>11/05/2010</approvaldate>
  <actrnumber>ACTRN12610000379011</actrnumber>
  <trial_identification>
    <studytitle>Single-ascending dose of CEP 37251 in Healthy Postmenopausal Women</studytitle>
    <scientifictitle>A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Characterize the Safety, Pharmacokinetics, and Pharmacodynamics of CEP 37251 in Healthy Postmenopausal Women</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Osteoporosis in Healthy Postmenopausal Women</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Menstruation and menopause</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>5 subcutaneous injection doses (sequentially) of CEP-37251 (0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg) will be studied. After all 5 subcutaneous injection doses have been studied, an intravenous infusion dose of 0.3 mg/kg will be studied. At each dose level, subjects will be divided into 3 cohorts. The first cohort will consist of 2 subjects (1 subject receiving CEP-37251 and 1 subject receiving placebo), the second cohort will consist of 3 subjects (2 subjects receiving CEP-37251 and 1 subject receiving placebo), and cohort 3 will consist of 4 subjects (3 subjects receiving CEP-37251 and 1 subject receiving placebo). There will be a minimum of 30 minutes between the start of study drug administration for each subject within a cohort. Each subject in both the subcutaneous injection and intravenous infusion groups will receive one dose only. There will be a minimum of 1 week between dose administration of the 1st and subsequent cohort(s) for each dose level. There is no minumum wait time between administration of the 2nd and 3rd cohorts in each dose level. The 2nd and 3rd cohorts of a dose level can be dosed in non-sequential order and can be dosed on the same day.</interventions>
    <comparator>Buffer solution containing 36 mM citric acid, 98 mM sodium phosphate, and 150 mM sodium chloride, pH 5.5 (identical in color and appearance to CEP-37251 drug product) will be used as placebo.  The placebo will be provided as a 1 mL extractable volume in a 2 mL vial.
The placebo for the first 5 doses will be given as subcutaneous injection. The placebo for the 6 dose group will be given as intravenous infusion.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary objective of this study is to assess the safety of CEP 37251 given by subcutaneous injection or intravenous infusion to healthy postmenopausal women</outcome>
      <timepoint>Subjects will be continuously monitored for the occurrence of adverse events, clinical laboratory test results, immunoglobulin measurements, biochemical panel test results, vital signs measurements, 12 lead Electrocardiogram findings, physical examination findings, injection-site evaluation findings, concomitant medication usage, immunophenotyping test results, and immunogenicity test results (from baseline to end of study). Subjects will be monitored (remain) at the study site for 48hrs after dose administration.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate the following characteristic of CEP-37251 over 70 days following a single subcutaneous injection or an intravenous infusion to healthy postmenopausal women
-The pharmacokinetic profile of CEP-37251</outcome>
      <timepoint>Urine samples will be obtained before study drug administration (minus 24 and 0 hours), 12, 24, and 48 hours after the start of study drug administration and on days 4, 5, 7, 14, 21, 28, 56, and 70.  Blood samples will be obtained before study drug administration (minus 24 and 0 hours), 24 and 48 hours after the start of study drug administration and on days 4, 5, 7, 14, 21, 28, 56, and 70.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate the following characteristic of CEP-37251 over 70 days following a single subcutaneous injection or an intravenous infusion to healthy postmenopausal women
- The pharmacodynamic effect of CEP-37251 as measured by markers of bone metabolism</outcome>
      <timepoint>Urine samples will be obtained before study drug administration (minus 24 and 0 hours), 12, 24, and 48 hours after the start of study drug administration and on days 4, 5, 7, 14, 21, 28, 56, and 70.  Blood samples will be obtained before study drug administration (minus 24 and 0 hours), 24 and 48 hours after the start of study drug administration and on days 4, 5, 7, 14, 21, 28, 56, and 70.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. The subject is a postmenopausal woman aged 40 years or greater but less than 75 years. 
2.The subject is considered to be postmenopausal if at least 1 of the following criteria is met: 1a) aged 50 or more years and has had a lack of menses for 12 or more months 1b) aged 40 or more and less than 50 years, has had a lack of menses for 12 or more months, and serum estradiol is 20 ng/mL or less or follicular stimulating hormone (FSH) is 50 IU/L or greater 1c) aged 40 or more years and has had bilateral surgical oophorectomy 1d) aged 40 or more years, has had a hysterectomy, and serum estradiol is 20 ng/mL or less or FSH is 50 IU/L or greater 
3. The subject has a body weight greater than 50 kg but no more than 100 kg with a body mass index (BMI) of 18 to 35 kg/m2</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>1 The subject has received any of the following medications within the 6 months prior to enrollment: 1a) hormone replacement therapy 1b) selective estrogen receptor modulator (SERM) therapy such as raloxifene 1c) elemental calcium supplementation &gt;1.5 g/day 1d) Vitamin D supplementation &gt;1000 IU per day 1e) calcitriol or other Vitamin D analogs of calcitrol (eg, alfacalcidol, doxercalciferol, or paricalcitol) 1f) calcitonin or parathyroid hormone 1g) glucocorticoids and/or anabolic steroids 
2 The subject has received bisphosphonates or fluoride within the 12 months prior to enrollment. 
3 The subject has any of the following concomitant conditions: 3a) hypo- or hyperthyroidism. NOTE: Subjects with treated hypothyroidism with normal thyroid parameters may be allowed to participate in the study at the discretion of the investigator and medical monitor. 3b) hypo- or hyperparathyroidism 3c) recent fracture (within 6 months) 3d) osteomalacia, Pagets Disease, osteopetrosis, osteogenesis imperfecta, or other bone disease 3e) rheumatoid arthritis or psoriatic arthritis 3f) acute osteoarthritis or gout 3g) chronic kidney disease or renal failure defined as an estimated glomerular filtration rate (eGFR) (by Modification of Diet in Renal Disease (MDRD) equation) 30 mL/min/1.73m2 or less 
4 The subject is receiving immunosuppressant drugs. 
5 The subject has evidence of severe, progressive, or uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, psychiatric, or cerebral disease, or malabsorption syndrome. 
6 The subject has a known history or evidence of malignancy, lymphoproliferative, or neoplastic disease with the exception of being successfully treated for basal or squamous cell carcinoma of the skin or cervical intraepithelial neoplasia. 
7 The subject has a known or suspected hypersensitivity or idiosyncratic reaction to any compound present in the study drug or placebo. 
8 The subject has habitually consumed, within the past 2 years, more than 21 units of alcohol per week, or has a history of alcohol, narcotic, or any other substance abuse as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR, American Psychiatric Association 2000). NOTE: A unit of alcohol is equal to approximately 30 ml of spirits, 100 ml of wine, or 260 ml of full-strength beer.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Other</assignment>
    <designfeatures>5 subcutaneous injection doses (sequentially) of CEP-37251 (0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg) will be studied. After all 5 subcutaneous injection doses have been studied, an intravenous infusion dose of 0.3 mg/kg will be studied. At each dose level, subjects will be divided into 3 cohorts. The first cohort will consist of 2 subjects (1 subject receiving CEP-37251 and 1 subject receiving placebo), the second cohort will consist of 3 subjects (2 subjects receiving CEP-37251 and 1 subject receiving placebo), and cohort 3 will consist of 4 subjects (3 subjects receiving CEP-37251 and 1 subject receiving placebo). There will be a minimum of 30 minutes between the start of study drug administration for each subject within a cohort. Each subject in both the subcutaneous injection and intravenous infusion groups will receive one dose only. There will be a minimum of 1 week between dose administration of the 1st and subsequent cohort(s) for each dose level. There is no minumum wait time between administration of the 2nd and 3rd cohorts in each dose level. The 2nd and 3rd cohorts of a dose level can be dosed in non-sequential order and can be dosed on the same day.</designfeatures>
    <endpoint>Safety</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>1/06/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>54</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Terminated</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Cephalon, Inc.</primarysponsorname>
    <primarysponsoraddress>41 Moores Road
Frazer, Pennsylvania 19355</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Cephalon, Inc.</fundingname>
      <fundingaddress>41 Moores Road
Frazer, Pennsylvania 19355</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Cephalon Australia Pty Ltd</sponsorname>
      <sponsoraddress>Level 2
37 Epping Road
Macquarie Park NSW 2113</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to characterize the safety, pharmacokinetics, and pharmacodynamics of CEP 37251 following single ascending doses in healthy postmenopausal women.  This study is intended to identify a dose of CEP-37251 having a sustained effect on biomarkers of bone resorption.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Bellberry Limited</ethicname>
      <ethicaddress>229 Greenhill Road
Dulwich  SA  5065</ethicaddress>
      <ethicapprovaldate>7/06/2010</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>5/05/2010</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Denise M. Dâ€™Andrea (Sr. Director, Clinical Pharmacology and Experimental Medicine)</name>
      <address>41 Moores Road
Frazer, Pennsylvania 19355</address>
      <phone>001-610-738-6897</phone>
      <fax />
      <email>ddandrea@cephalon.com</email>
      <country>United States of America</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Jane Kelly</name>
      <address>CMAX, A division of
Institute of Drug Technology (IDT) Australia Ltd
Level 5 East Wing
Royal Adelaide Hospital
North Terrace, Adelaide, 5000 
S.A</address>
      <phone>+61 8 8222 3931</phone>
      <fax />
      <email>cmax@cmax.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Sharna Lawson</name>
      <address>124 Lipson Street, Port Adelaide, SA 5015</address>
      <phone />
      <fax />
      <email>slawson@tridentclinicalresearch.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>